Intraperitoneal Bupivacaine for Pelvic Organ Prolapse
Completed · Phase 4 · Has a placebo group
Conditions studied: Pelvic Organ Prolapse
In brief
The purpose of this study is to evaluate the effects of 30 mL intraperitoneal Bupivacaine without epinephrine 0.25% on postoperative pain control in patients undergoing pelvic organ prolapse repair. The investigators hypothesize that use of intraperitoneal Bupivacaine will decrease postoperative pain scores and opiate consumption in the postoperative period, following pelvic organ prolapse repair.
Key facts
- Study ID
- NCT06120530
- Run by
- Indiana University
- People needed
- 91
- Starts
- 2023-08-16
- Expected to finish
- 2024-03-15
- Last updated by the study team
- 2025-04-20
Who can join
Age: 18 and older, up to 90. Sex: female. Healthy volunteers: not accepted.
Where it is running
- IU north — Carmel, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.